Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

TYRA-200

Small molecule · Inhibitor of FGFR1, FGFR2 and FGFR3 · developed by Tyra Biosciences

Phase 1 Most advanced trial
TYRA Developer
1 Registered trials

What is TYRA-200?

TYRA-200 is an oral tyrosine kinase inhibitor of FGFR1, FGFR2 and FGFR3. It is designed to target tumors that carry activating gene alterations of FGFR2. It is being studied in cholangiocarcinoma and other solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
FGFR1, FGFR2, FGFR3
Mechanism
Inhibitor of FGFR1, FGFR2 and FGFR3
Therapy area
Oncology
Developer
Tyra Biosciences, Inc (TYRA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06160752 Phase 1 Locally Advanced Cholangiocarcinoma Active not recruiting TYRA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Intrahepatic CholangiocarcinomaLocally Advanced CholangiocarcinomaMetastatic CholangiocarcinomaSolid Tumor

Other drugs acting on FGFR1 / FGFR2 / FGFR3

More from Tyra Biosciences

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TYRA page.

Follow TYRA, the company behind TYRA-200

See TYRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TYRA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.